Mantle cell lymphoma (MCL) is a distinct entity of lymphoma in the WHO classification1 and represents approximately 5-6% of all non-Hodgkin's lymphomas.2 The incidence of MCL is 2-3 per 100,000/year and occurs with at a median age of 65 years. Classical nodal and extra-nodal MCL is associated with overexpression of Cyclin D1 from the presence of the t(11;14) (q13; q32) translocation juxtaposing the BCL1 gene and the immunoglobulin heavy chain locus.3-5 MCL exhibits a strong tendency toward extranodal involvement, especially the gastrointestinal tract,6 bone marrow, and spleen. The approach to staging is similar to aggressive lymphomas, and also includes colonoscopy due to a high incidence of lower GI tract involvement.7 MCL has moderate chemosensitivity, with complete responses to conventional chemotherapy ranging from 20% to 60%.8-10 Despite this, the disease has a dismal outcome and tends to recur following conventional therapy, with a median survival of 3 years.11-13

0 0

Post a comment